Aton (Shanghai) Biotech Co., Ltd. is a rapidly growing biopharmaceutical Contract Development and Manufacturing Organization (CDMO). Aton prioritizes quality and is dedicated to empowering integrated biopharmaceutical drug development and manufacturing, enabling customers to accelerate their pipeline to market. Aton’s services cover end-to-end CDMO services from cell line construction to commercial manufacturing, including the development and production of monoclonal antibodies, fusion proteins, bispecific antibodies, ADCs (Antibody Drug Coupling Compounds), etc. Now Aton is equipped with two R&D and manufacturing sites, supported by a quality management system that meets the requirements of the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and China’s National Medical Products Administration (NMPA). In addition to the industry-leading manufacturing technology platform, Aton has established a first-in-class biopharmaceutical R&D, manufacturing, and operational management team with a high-quality talent reserve and a robust team structure. The core management team has an average of more than 15 years of senior management experience in the industry and possesses professional management expertise in R&D, clinical, manufacturing, CMC, quality, and compliance from leading multinational pharmaceutical companies.